These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35761402)

  • 41. An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies.
    Zhang N; Shang J; Li C; Zhou K; Du L
    Expert Rev Vaccines; 2020 Sep; 19(9):817-829. PubMed ID: 32842811
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.
    Choi JA; Kim JO
    J Microbiol; 2022 Mar; 60(3):238-246. PubMed ID: 35089585
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.
    Song F; Fux R; Provacia LB; Volz A; Eickmann M; Becker S; Osterhaus AD; Haagmans BL; Sutter G
    J Virol; 2013 Nov; 87(21):11950-4. PubMed ID: 23986586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations in the Spike Protein of Middle East Respiratory Syndrome Coronavirus Transmitted in Korea Increase Resistance to Antibody-Mediated Neutralization.
    Kleine-Weber H; Elzayat MT; Wang L; Graham BS; Müller MA; Drosten C; Pöhlmann S; Hoffmann M
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus.
    Lee K; Ko HL; Lee EY; Park HJ; Kim YS; Kim YS; Cho NH; Park MS; Lee SM; Kim J; Kim H; Seong BL; Nam JH
    Microbiol Immunol; 2018 Sep; 62(9):574-584. PubMed ID: 30117617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A mouse model for Betacoronavirus subgroup 2c using a bat coronavirus strain HKU5 variant.
    Agnihothram S; Yount BL; Donaldson EF; Huynh J; Menachery VD; Gralinski LE; Graham RL; Becker MM; Tomar S; Scobey TD; Osswald HL; Whitmore A; Gopal R; Ghosh AK; Mesecar A; Zambon M; Heise M; Denison MR; Baric RS
    mBio; 2014 Mar; 5(2):e00047-14. PubMed ID: 24667706
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancing immune protection against MERS-CoV: the synergistic effect of proteolytic cleavage sites and the fusion peptide and RBD domain targeting VLP immunization.
    Oh J; Park U; Kim J; Jeon K; Kim C; Cho NH; Choi YS
    Front Immunol; 2023; 14():1201136. PubMed ID: 37275866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins.
    Chen J; Xu W; Li L; Yi L; Jiang Y; Hao P; Xu Z; Zou W; Li P; Gao Z; Tian M; Jin N; Ren L; Li C
    Front Cell Infect Microbiol; 2022; 12():967493. PubMed ID: 35923799
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
    Tang XC; Agnihothram SS; Jiao Y; Stanhope J; Graham RL; Peterson EC; Avnir Y; Tallarico AS; Sheehan J; Zhu Q; Baric RS; Marasco WA
    Proc Natl Acad Sci U S A; 2014 May; 111(19):E2018-26. PubMed ID: 24778221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein.
    Widjaja I; Wang C; van Haperen R; Gutiérrez-Álvarez J; van Dieren B; Okba NMA; Raj VS; Li W; Fernandez-Delgado R; Grosveld F; van Kuppeveld FJM; Haagmans BL; Enjuanes L; Drabek D; Bosch BJ
    Emerg Microbes Infect; 2019; 8(1):516-530. PubMed ID: 30938227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein.
    Goo J; Jeong Y; Park YS; Yang E; Jung DI; Rho S; Park U; Sung H; Park PG; Choi JA; Seo SH; Cho NH; Lee H; Lee JM; Kim JO; Song M
    Virus Res; 2020 Mar; 278():197863. PubMed ID: 31945421
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MERS-CoV spike protein: Targets for vaccines and therapeutics.
    Wang Q; Wong G; Lu G; Yan J; Gao GF
    Antiviral Res; 2016 Sep; 133():165-77. PubMed ID: 27468951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Chimeric Sudan Virus-Like Particle Vaccine Candidate Produced by a Recombinant Baculovirus System Induces Specific Immune Responses in Mice and Horses.
    Wu F; Zhang S; Zhang Y; Mo R; Yan F; Wang H; Wong G; Chi H; Wang T; Feng N; Gao Y; Xia X; Zhao Y; Yang S
    Viruses; 2020 Jan; 12(1):. PubMed ID: 31947873
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subunit vaccines with a saponin-based adjuvant boost humoral and cellular immunity to MERS coronavirus.
    Chang CC; Algaissi A; Lai CC; Chang CK; Lin JS; Wang YS; Chang BH; Chang YC; Chen WT; Fan YQ; Peng BH; Chao CY; Tzeng SR; Liang PH; Sung WC; Hu AY; Chang SC; Chang MF
    Vaccine; 2023 May; 41(21):3337-3346. PubMed ID: 37085450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of virus-like particles-based vaccines against coronaviruses.
    Yong CY; Liew WPP; Ong HK; Poh CL
    Biotechnol Prog; 2022 Nov; 38(6):e3292. PubMed ID: 35932092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Middle East Respiratory Syndrome Coronavirus Gene 5 Modulates Pathogenesis in Mice.
    Gutierrez-Alvarez J; Wang L; Fernandez-Delgado R; Li K; McCray PB; Perlman S; Sola I; Zuñiga S; Enjuanes L
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33144319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.
    Haagmans BL; van den Brand JM; Raj VS; Volz A; Wohlsein P; Smits SL; Schipper D; Bestebroer TM; Okba N; Fux R; Bensaid A; Solanes Foz D; Kuiken T; Baumgärtner W; Segalés J; Sutter G; Osterhaus AD
    Science; 2016 Jan; 351(6268):77-81. PubMed ID: 26678878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein.
    Du L; Zhao G; Yang Y; Qiu H; Wang L; Kou Z; Tao X; Yu H; Sun S; Tseng CT; Jiang S; Li F; Zhou Y
    J Virol; 2014 Jun; 88(12):7045-53. PubMed ID: 24719424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of candidate vaccine approaches for MERS-CoV.
    Wang L; Shi W; Joyce MG; Modjarrad K; Zhang Y; Leung K; Lees CR; Zhou T; Yassine HM; Kanekiyo M; Yang ZY; Chen X; Becker MM; Freeman M; Vogel L; Johnson JC; Olinger G; Todd JP; Bagci U; Solomon J; Mollura DJ; Hensley L; Jahrling P; Denison MR; Rao SS; Subbarao K; Kwong PD; Mascola JR; Kong WP; Graham BS
    Nat Commun; 2015 Jul; 6():7712. PubMed ID: 26218507
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
    Zhang N; Channappanavar R; Ma C; Wang L; Tang J; Garron T; Tao X; Tasneem S; Lu L; Tseng CT; Zhou Y; Perlman S; Jiang S; Du L
    Cell Mol Immunol; 2016 Mar; 13(2):180-90. PubMed ID: 25640653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.